EMAIL THIS PAGE TO A FRIEND

Toxicology letters

A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity.


PMID 25127758

Abstract

Acquired cardiac long QT syndrome (LQTS) is a frequent drug-induced toxic event that is often caused through blocking of the human ether-á-go-go-related (hERG) K(+) ion channel. This has led to the removal of several major drugs post-approval and is a frequent cause of termination of clinical trials. We report here a computational atomistic model derived using long molecular dynamics that allows sensitive prediction of hERG blockage. It identified drug-mediated hERG blocking activity of a test panel of 18 compounds with high sensitivity and specificity and was experimentally validated using hERG binding assays and patch clamp electrophysiological assays. The model discriminates between potent, weak, and non-hERG blockers and is superior to previous computational methods. This computational model serves as a powerful new tool to predict hERG blocking thus rendering drug development safer and more efficient. As an example, we show that a drug that was halted recently in clinical development because of severe cardiotoxicity is a potent inhibitor of hERG in two different biological assays which could have been predicted using our new computational model.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

284785
(S)-(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, 98%
C14H14O3
A7302
4-Acetamidophenol, 98%
C8H9NO2
A7085
Acetaminophen, BioXtra, ≥99.0%
C8H9NO2
A3035
Acetaminophen, analytical standard
C8H9NO2
A5000
Acetaminophen, meets USP testing specifications, 98.0-102.0%, powder
C8H9NO2
1003009
Acetaminophen, United States Pharmacopeia (USP) Reference Standard
C8H9NO2
PHR1005
Acetaminophen, Pharmaceutical Secondary Standard; Certified Reference Material
C8H9NO2
A-064
Acetaminophen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C8H9NO2
A5376
Acetylsalicylic acid, ≥99.0%
C9H8O4
A3160
Acetylsalicylic acid, analytical standard
C9H8O4
A0200000
Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard
C9H8O4
A6810
Acetylsalicylic acid, BioReagent, plant cell culture tested, ≥99.0%
C9H8O4
Y0001460
Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard
C9H8O4
1044006
Aspirin, United States Pharmacopeia (USP) Reference Standard
C9H8O4
A2093
Aspirin, meets USP testing specifications
C9H8O4
PHR1003
Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard; Certified Reference Material
C9H8O4
A2861
Astemizole, ≥98% (HPLC)
C28H31FN4O
PZ0008
Celecoxib, ≥98% (HPLC)
C17H14F3N3O2S
Y0001445
Celecoxib, European Pharmacopoeia (EP) Reference Standard
C17H14F3N3O2S
M5060
E-4031, ≥98% (HPLC), solid
C21H27N3O3S · 2HCl
G6752
Guanosine, ≥98%
C10H13N5O5
G6264
Guanosine, suitable for cell culture, BioReagent
C10H13N5O5
75903
Guanosine, ≥97.0% (HPLC)
C10H13N5O5
H1512
Haloperidol, powder
C21H23ClFNO2
H100
Haloperidol
C21H23ClFNO2
H0100000
Haloperidol, European Pharmacopoeia (EP) Reference Standard
C21H23ClFNO2
1303002
Haloperidol, United States Pharmacopeia (USP) Reference Standard
C21H23ClFNO2
Y0001518
Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard
C21H23ClFNO2
Y0001517
Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard
C21H23ClFNO2
I4883
Ibuprofen, ≥98% (GC)
C13H18O2